Targeted Oncology9d
FDA Grants Priority Review to Zongertinib in HER2-Mutant NSCLC
Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...
The New England Journal of Medicine24d
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicating greater disability. Rai stages 0 to II indicate low or intermediate risk of ...
ascopubs.org11d
Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for renal cell carcinoma (RCC).
Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024). LITESPARK-005, KEYNOTE-564, TIVO-3, CLEAR, CHECKMATE-9ER, ...
Too Old to Operate3d
Acalabrutinib Combinations Improve Survival in Untreated CLL
Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia,” published in the February 2025 issue of New England Journal of Medicine by R. Brown et al. Researchers conducted a ...
ascopubs.org11d
Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for urothelial cancer.
This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text component.
Morningstar2mon
L&G Ecommerce Logistics ETF
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...